- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00663975
Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients
An Open-Label, Multi-Center Safety and Efficacy Study of DCI-1020 in Pediatric Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency
Hypothesis:DCI 1020 capsules are safe and effective in treating exocrine pancreatic insufficiency in CF patients <= 2 years of age.
The results of this study are intended to be submitted to the FDA as part of the NDA package for marketing approval of PANCRECARB (DCI 1020).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A large body of data supporting the safety and efficacy of PANCRECARB® (pancrelipase) Capsules is available in patients above age 2. This study is being performed to gather the data to demonstrate the safety and efficacy of DCI1020 in pediatric CF patients (≤ 2 years) with exocrine pancreatic insufficiency. This study also takes into consideration an "age appropriate" dosing form. Specifically, the enzymes will be administered orally by opening the capsules and emptying the microspheres into a small amount of applesauce as an example of a slightly acidic soft food such as jelly, jello, etc. for feeding.
The results of this study are intended to be submitted to the FDA as part of the NDA package for marketing approval of PANCRECARB® DCI 1020(pancrelipase).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Rainbow Babies and Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female age ≤ 2 years of age
- Confirmed diagnosis of CF based on the following criteria:
- One or more clinical features consistent with the CF phenotype, AND
- Positive sweat chloride ≥ 60 mEq/liter (by pilocarpine iontophoresis), OR
- Genotype with two identifiable mutations consistent with CF
- Adequate nutritional status
- Pancreatic insufficiency documented by spot fecal elastase-1 (FE 1) greater or equal to 100 micrograms/g stool
- Clinically stable with no evidence of an acute medical condition
- Parent/Guardian able to understand and sign a written informed consent and comply with the requirements of the study
Exclusion Criteria:
- History of fibrosing colonopathy
- History of being refractory to pancreatic enzyme replacement therapy
- Solid organ transplant
- History of intra-abdominal surgery
- A current diagnosis or a history of distal intestinal obstruction syndrome (DIOS) in the past six (6) months, or 2 or more episodes of DIOS in the past twelve (12) months
- Conditions known to increase fecal fat loss including: inflammatory bowel disease , celiac disease, Crohn's disease, tropical Sprue, Whipple's disease
- A known contraindication, sensitivity or hypersensitivity to porcine pancreatic enzymes
- Active liver disease with liver enzymes (alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT) or bilirubin ≥ 3 times the upper limit of normal
- Acute pancreatitis or acute exacerbation of chronic pancreatitis
- Antibiotic use as follows:
- Acute treatment with any systemic (oral or IV) antibiotics two (2) weeks prior to screening
- Treatment with erythromycin and unwilling to discontinue the treatment two (2) weeks prior to the screening. (azithromycin is allowed)
- Change in chronic treatment with systemic (oral and IV) antibiotics during the trial
NOTE:
Study patient may remain on a chronic regimen of systemic (oral or IV) antibiotics (with exception of erythromycin), if he/she started the antibiotics at least 2 weeks prior to study screening, was at his/her usual bowel pattern at the time of screening, and does not stop or change these antibiotics during the study.
- Receiving enteral tube feeding during the study
- Breast feeding during the study (expressed breast milk may be used, but not feeding at the breast)
- Expected inability to cooperate with or be non-adherent to required study procedures
- Use of narcotics
- Poorly controlled diabetes
- Participation in an investigational study of a drug, biologic, or device not currently approved for marketing, within 30 days of screening visit
- A medical condition which the investigator deems significant enough to interfere with the ability of the study patient to participate in the trial or interfering with assessment of effects of enzyme therapy on fat absorption
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
DCI-1020 Capsules contain an enteric-coated buffered microspheres of pancrelipase, encapsulated in clear capsules.
Capsules are equivalent to 4,000 USP units of lipase
|
capsules (4,000 units of lipase) will be administered with meals and snacks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quantitative fecal fat content (%of fat/g of dry stool) in the spot stool samples collected over the 3 day In-home Treatment Period
Time Frame: 3 consecutive days
|
3 consecutive days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Tibor Sipos, PhD, DCI
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DCI 07-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Digestive System Diseases
-
Suzhou Immunofoco Biotechnology Co., LtdRecruitingAdvanced Digestive System TumorChina
-
Zhejiang Doer Biologics Co., Ltd.RecruitingMalignant Neoplasm of Digestive SystemChina
-
Peking University Cancer Hospital & InstituteRecruitingDigestive System CancersChina
-
Changhai HospitalShanghai Ultra-T Immune Therapeutics Co. LTDNot yet recruiting
-
The First Affiliated Hospital with Nanjing Medical...Active, not recruitingDigestive System CancerChina
-
Mahidol UniversityCompletedDigestive System CancerThailand
-
Innovative Cellular Therapeutics Co., Ltd.Anhui Provincial Cancer HospitalNot yet recruiting
-
University Hospital FreiburgCompletedDigestive System Diseases [C06] | Digestive System Neoplasms [C04.588.274]Germany
-
Peking UniversityRecruitingAdvanced Malignant Solid Tumor of Digestive SystemChina
-
Amway CorpCitruslabsCompletedDigestive System DiseaseUnited States
Clinical Trials on DCI 1020
-
Neurovance, Inc.CompletedNormal, Healthy VolunteersAustralia
-
Masimo CorporationCompleted
-
Bristol-Myers SquibbCardioxyl Pharmaceuticals, IncCompletedHeart FailureUnited States
-
Bristol-Myers SquibbCardioxyl Pharmaceuticals, IncCompletedHeart FailureUnited States
-
Masimo CorporationCompleted
-
Athira PharmaBiotrial Inc.; Alturas Analytics, Inc.Completed
-
Masimo CorporationCompleted
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAttention Deficit Hyperactivity DisorderUnited States
-
Avidity Biosciences, Inc.RecruitingPhase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE)Muscular Dystrophies | Muscular Dystrophy, Facioscapulohumeral | FSHD | Facio-Scapulo-Humeral Dystrophy | FMD | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | FMD2 | Fascioscapulohumeral Muscular Dystrophy | Fascioscapulohumeral Muscular Dystrophy Type 1 | Fascioscapulohumeral Muscular Dystrophy... and other conditionsUnited States, United Kingdom, Canada
-
Hillel Yaffe Medical CenterUnknownBorderline Personality DisorderIsrael